Michael Rafii, MD, PhD, discusses the need for equity and inclusivity in Alzheimer's research to improve the lives of people with Down syndrome. JAMA, Nov. 2023
Lead researcher for TRC-DS, Michael Rafii, MD, PhD, participated in a congressional briefing on the status of research on Alzheimer’s disease in people with Down syndrome. ATRI, July 2023
Thirty years ago, the Down syndrome community helped scientists uncover critical learnings about the genetic basis of Alzheimer’s disease. Now, in 2023, we stand on the cusp of new treatments reaching the market. Fierce Biotech, March 2023
People with Down syndrome, which causes intellectual and physical disabilities, are almost never included in clinical trials for drugs to treat or prevent Alzheimer’s, a situation advocates, patients and scientists decry and are trying to change. Washington Post, April 2022
By the time they’re 40, most people with Down syndrome develop beta amyloid plaques in the brain — a key characteristic of Alzheimer’s disease. UC Irvine Health, March 2021
When researchers at the University of California, San Diego wanted to study an experimental Alzheimer's drug last year, they sought help from an unlikely group: people with Down syndrome. NPR, Aug. 2014
